Harangi Mariann, Seres Ildikó, Varga Zsuzsa, Emri Gabriella, Szilvássy Zoltán, Paragh György, Remenyik Eva
1st Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.
Eur J Clin Pharmacol. 2004 Dec;60(10):685-91. doi: 10.1007/s00228-004-0820-6. Epub 2004 Oct 14.
High-density lipoprotein (HDL)-associated antioxidant paraoxonase (PON) may reduce low-density lipoprotein (LDL) oxidation and prevent atherosclerosis. The aim of this present study was to investigate the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor atorvastatin on hydrogen-peroxide-induced DNA damage by comet assay and the correlation between oxidative DNA damage and antioxidant PON activity.
Thirteen type-II/a hyperlipidemic patients were enrolled in the study. We examined the effect of 10 mg/day atorvastatin treatment on lipid levels and the degree of DNA damage in lymphocytes separated from hyperlipidemic patients, nitric oxide (NO), thiobarbituric acid-reactive substances (TBARS), PON levels and activity.
After 6 months, atorvastatin treatment significantly decreased serum cholesterol and LDL-cholesterol levels. The triglyceride level did not change, and there was no significant change in the HDL cholesterol level. The visual score characteristic to the degree of DNA damage in comet assay was significantly decreased, as well as the TBARS level, while the level of NO was non-significantly increased. PON activity and the PON/HDL ratio were significantly increased after atorvastatin treatment. There was a negative correlation between DNA damage and PON activity, as well as between DNA damage and the PON/HDL ratio before and after atorvastatin treatment.
These findings show that atorvastatin treatment favorably affected the lipid profile, increasing the activity of HDL-associated PON and decreasing the cytotoxic effect of oxidative stress.
高密度脂蛋白(HDL)相关的抗氧化对氧磷酶(PON)可能会减少低密度脂蛋白(LDL)氧化并预防动脉粥样硬化。本研究的目的是通过彗星试验研究3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂阿托伐他汀对过氧化氢诱导的DNA损伤的影响,以及氧化DNA损伤与抗氧化PON活性之间的相关性。
13名II/a型高脂血症患者参与了本研究。我们检测了每天10毫克阿托伐他汀治疗对高脂血症患者分离的淋巴细胞中血脂水平、DNA损伤程度、一氧化氮(NO)、硫代巴比妥酸反应性物质(TBARS)、PON水平和活性的影响。
6个月后,阿托伐他汀治疗显著降低了血清胆固醇和低密度脂蛋白胆固醇水平。甘油三酯水平未改变,高密度脂蛋白胆固醇水平也无显著变化。彗星试验中DNA损伤程度的视觉评分显著降低,TBARS水平也显著降低,而NO水平略有升高但无统计学意义。阿托伐他汀治疗后PON活性和PON/HDL比值显著升高。在阿托伐他汀治疗前后,DNA损伤与PON活性之间以及DNA损伤与PON/HDL比值之间均呈负相关。
这些发现表明,阿托伐他汀治疗对血脂谱有有利影响,增加了HDL相关PON的活性,并降低了氧化应激的细胞毒性作用。